The insect steroid hormone 20-hydroxyecdysone (20E) acts through a specific nuclear receptor complex, ecdysone receptor (EcR) and ultraspiracle (USP). EcR and USP are FXR/LXR and RXR orthologs, respectively, which play critical roles in the regulation of lipid metabolism in mammals. Lipid concentration in Bombyx hemolymph and lipase activity in fat body peaked during molting and pupation, suggesting that 20E induces lipolysis at these stages. Differing from their mammalian orthologs, the 20E-bound EcR-USP was not able to directly stimulate fat body lipolysis in both Bombyx and Drosophila. Instead in Bombyx, 20E slowly reduced food consumption and then induced starvation, resulting in fat body lipolysis. Molecular analysis revealed that the evolutionarily conserved adipose triacylglycerol lipase gene Brummer was transcriptionally up-regulated by 20E-induced starvation during molting and pupation. To our knowledge, this is the first report demonstrating that the steroid hormone 20E is a critical regulator of lipolysis in insects.

BRAF hyperactivates ERK and signals as a RAF inhibitor-sensitive monomer. Although RAF inhibitors can produce impressive clinical responses in patients with mutant tumors, the mechanisms of resistance to these drugs are incompletely characterized. Here, we report a complete response followed by clinical progression in a patient with a-mutant brain tumor treated with dabrafenib. Whole-exome sequencing revealed a secondary mutation at progression that was not present in the pretreatment tumor. Expressing BRAF induces ERK signaling, promotes RAF dimer formation, and is sufficient to confer resistance to dabrafenib. Newer RAF dimer inhibitors and an ERK inhibitor are effective against BRAF-mediated resistance. Collectively, our results validate a novel biochemical mechanism of RAF inhibitor resistance mediated by a secondary mutation, emphasizing that, like driver mutations in cancer, the spectrum of mutations that drive resistance to targeted therapy are heterogeneous and perhaps emerge with a lineage-specific prevalence. In contrast to receptor tyrosine kinases, in which secondary mutations are often responsible for acquired resistance, second-site mutations in have not been validated in clinically acquired resistance to RAF inhibitors. We demonstrate a secondary mutation in (V600E/L514V) following progression on dabrafenib and confirm functionally that this mutation is responsible for resistance. .

Malignant peripheral nerve sheath tumors often arise in patients with neurofibromatosis type 1 and are among the most treatmentrefractory types of sarcoma. Overall survival in patients with relapsed disease remains poor, and thus novel therapeutic approaches are needed. NF1 is essential for negative regulation of RAS activity and is altered in about 90% of malignant peripheral nerve sheath tumors (MPNST). A complex interplay of upstream signaling and parallel RAS-driven pathways characterizes NF1driven tumorigenesis, and inhibiting more than one RAS effector pathway is therefore necessary. To devise potential combination therapeutic strategies, we identified actionable alterations in signaling that underlie adaptive and acquired resistance to MEK inhibitor (MEKi). Using a series of proteomic, biochemical, and genetic approaches in an in vitro model of MEKi resistance provided a rationale for combination therapies. HGF/MET signaling was elevated in the MEKi-resistant model. HGF overexpression conferred resistance to MEKi in parental cells. Depletion of HGF or MET restored sensitivity of MEKi-resistant cells to MEKi. Finally, a combination of MEK and MET inhibition demonstrated activity in models of MPNST and may therefore be effective in patients with MPNST harboring genetic alterations in NF1.Significance: This study demonstrates that MEKi plus MET inhibitor may delay or prevent a novel mechanism of acquired MEKi resistance, with clinical implications for MPNST patients harboring NF1 alterations.